COSMNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Cosmos Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.33−0.01 (-1.90%)
Close on Oct 19, 2026
- Market cap
- $19.48M
- P/E (TTM)
- –
- Dividend yield
- –
Cosmos Health Inc. revenue by segment
By business segment
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q4 23 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q4 18 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wholesale [Member] | $63.71M | $59.32M | $50.74M | – | – | – | – | – | – | – | – | – | 91.7% |
| Nutraceuticals and Pharmaceuticals [Member] | $4.12M | $4.26M | – | – | – | – | – | – | – | – | – | – | 5.9% |
| Pharma manufacturing [Member] | $1.66M | $1.69M | $344.71K | – | – | – | – | – | – | – | – | – | 2.4% |
| Other [Member] | $1.71K | $1.23K | – | – | – | – | – | – | – | – | – | – | 0.0% |
By product or service
By region
From the segment and revenue-disaggregation notes of Cosmos Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.